Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239743 | 1.00 | LMNA (0.32) | LMNAGAAOPRK1OPRM1 | |
| SCHEMBL444276 | 0.75 | FNTA (0.48) | LMNAGAA | |
| SCHEMBL29372490 | 0.75 | FNTA (0.48) | LMNAGAA | |
| SCHEMBL5371230 | 0.74 | LMNA (0.39) | LMNAGAAOPRK1 | |
| SCHEMBL4685444 | 0.68 | LMNA (0.43) | LMNAGAAOPRK1 | |
| SCHEMBL7840054 | 0.67 | FNTA (0.49) | LMNAGAAOPRK1 | |
| SCHEMBL4685441 | 0.67 | LMNA (0.42) | LMNAGAAOPRK1 | |
| SCHEMBL446699 | 0.62 | FNTA (0.53) | LMNAGAAOPRK1 | |
| SCHEMBL1507983 | 0.62 | CYP19A1 (0.51) | — | |
| SCHEMBL7832580 | 0.62 | FNTA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4552697-A2 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| EP-3514151-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-12-16 | — | — | US | disclosed |
| CN-113214246-A | Protein kinase C inhibitors and methods of their use | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2021-07-13 | — | — | US | disclosed |
| CN-106795151-B | Protein kinase C inhibitors and methods of their use | 诺华股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20200262814-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2020-08-20 | — | — | US | disclosed |
| EP-3177608-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-2010528-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | Novartis Pharma AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2008144062-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008140850-A1 | SOLID FORMS OF A RAF KINASE INHIBITOR | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008082730-A2 | BIOMARKERS OF TARGET MODULATION, EFFICACY, DIAGNOSIS AND/OR PROGNOSIS FOR RAF INHIBITORS | NOVARTIS AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
| WO-2007121484-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2007-07-12 | — | — | US | disclosed |
| US-20050043357-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | BRAF, DSTYK, CHEK2 | LMNA 2953/4885GAA 1220/4885OPRK1 930/4885 |
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | LMNA 1775/4885GAA 1136/4885OPRK1 881/4885 |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | LMNA 1775/4885GAA 1136/4885OPRK1 881/4885 |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | LMNA 1775/4885GAA 1136/4885OPRK1 881/4885 |
| US-20050043357-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | LMNA 3380/4885GAA 1001/4885OPRK1 3846/4885 |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | LMNA 1775/4885GAA 1136/4885OPRK1 881/4885 |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | CSF1R, CSF3R, FLT3 | LMNA 4357/4885GAA 2417/4885OPRK1 820/4885 |
| US-20200262814-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | LMNA 1775/4885GAA 1136/4885OPRK1 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.